Are there clinical trials suitable for treating recurrent Prostate Cancer, and how can I determine if I am eligible

Clinical Trials for Recurrent Prostate Cancer: Your Options & Eligibility

I can see from your medical profile that you've had extensive genomic testing, including evaluation of important DNA repair genes (ATM and TP53 abnormalities noted). This is excellent information that may open doors to specific clinical trials. Let me walk you through how clinical trials work for recurrent prostate cancer and what makes you potentially eligible.

---

Understanding Clinical Trials for Recurrent Prostate Cancer

What "recurrent" means in this context: Recurrent prostate cancer typically refers to cancer that returns after initial treatment—either as rising PSA levels (PSA recurrence), local recurrence in the prostate area, or metastatic disease (cancer that has spread). According to the NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer, testing and monitoring are crucial to catch recurrence early.

Clinical trials are research studies testing new treatments or new combinations of existing treatments. For recurrent prostate cancer, trials may test:

• New hormone therapies (second-line treatments after initial hormone therapy fails)
• PARP inhibitors (drugs targeting DNA repair defects)
• Radioligand therapies like Lutetium-177 PSMA (Pluvicto)
• Immunotherapies and combination approaches
• Advanced imaging to better detect and monitor disease

---

Key Clinical Trials Currently Recruiting

Based on your genomic profile, here are specific trials that may be relevant:

1) PARP Inhibitors for HRR-Mutated Prostate Cancer (FDA-Approved)

Why this matters for you: Your testing shows ATM abnormality and TP53 abnormality—both are homologous recombination repair (HRR) genes. This is significant because:

• PARP inhibitors (like olaparib, rucaparib, niraparib) are FDA-approved for metastatic castration-resistant prostate cancer (mCRPC) with HRR mutations
• The PROfound trial demonstrated that patients with BRCA1/BRCA2, ATM, or CDK12 mutations had improved outcomes with PARP inhibitors
• According to NCCN Guidelines, testing for HRR mutations is now recommended for all patients with mCRPC

Relevant Clinical Trials:

• NCT02987543 - PARP inhibitor trial for HRR-mutated prostate cancer
• NCT02975934 - Additional PARP inhibitor study

Questions to ask your oncologist:

1. "Based on my ATM and TP53 abnormalities, am I eligible for PARP inhibitor trials?"
2. "Have I progressed to castration-resistant disease, which would make me eligible for these trials?"
3. "What are the eligibility criteria regarding prior treatments?"

---

2) Lutetium-177 PSMA (Pluvicto) - FDA-Approved 2022

What it is: A radioligand therapy—a targeted treatment that delivers radiation directly to prostate cancer cells that express PSMA (prostate-specific membrane antigen).

Why it's relevant:

• Approved for PSMA-positive, metastatic castration-resistant prostate cancer (mCRPC)
• The VISION trial showed improved overall survival in patients who had already received hormone therapy and chemotherapy
• Works by targeting PSMA on cancer cell surfaces

Relevant Clinical Trial:

• NCT03511664 - VISION trial and related studies

Questions to ask your oncologist:

1. "Do I have PSMA-positive disease? (This requires PSMA PET imaging)"
2. "Have I progressed through prior hormone therapy and/or chemotherapy?"
3. "Am I eligible for Lutetium-177 PSMA therapy?"

---

3) Advanced PSMA Imaging Trial - 18F-PSMA-1007 PET/CT

What it is: A newer imaging technology that may better detect prostate cancer spread than standard imaging.

Trial Details:

• NCT05520255 - Phase III study of 18F-PSMA-1007 PET/CT imaging
• Status: Currently recruiting
• Target population: Adults ≥18 years with history of radical prostatectomy for prostate cancer
• Study period: 2022-2028

Why this matters: Better imaging can help:

• Detect recurrence earlier
• Guide treatment decisions more precisely
• Identify which patients might benefit from specific therapies

Questions to ask your oncologist:

1. "Am I eligible for this imaging trial based on my treatment history?"
2. "Could this imaging help determine my eligibility for other trials?"
3. "Is this imaging available at my cancer center?"

---

How to Determine Your Eligibility

Step 1: Understand Your Current Disease Status According to NCCN Guidelines, your eligibility depends on:

• Whether you have localized recurrence (PSA rising after surgery) or metastatic disease
• Your current PSA level and PSA doubling time
• Whether you're hormone-sensitive or hormone-resistant
• Prior treatments you've received
• Your overall health and performance status

Step 2: Review Your Genomic Results Your testing already includes:

• ✅ ATM (abnormal) - makes you potentially eligible for PARP inhibitor trials
• ✅ TP53 (abnormal) - relevant for certain trials
• ✅ BRCA2 (tested) - critical for PARP inhibitor eligibility
• ✅ CDK12 (tested) - another HRR gene relevant to PARP trials
• ✅ Other DNA repair genes (RAD51C, PALB2, NBN, MRE11A, MLH1, FANCA, CHEK2, ATM)

This is excellent—you have the genomic data trials are looking for.

Step 3: Search for Trials Yourself

• Visit ClinicalTrials.gov and search:
  • "prostate cancer recurrent" + your location
  • "PARP inhibitor prostate"
  • "PSMA prostate cancer"
  • "lutetium-177 prostate"
• Filter by: recruiting status, your location, your disease stage

Step 4: Ask Your Oncology Team According to NCCN Guidelines, your care team should discuss clinical trial options with you. Specific questions:

---

Questions to Ask Your Oncology Team About Clinical Trials

About your eligibility:

1. "Based on my genomic testing (ATM and TP53 abnormalities), which clinical trials am I eligible for?"
2. "What is my current disease status—do I have localized recurrence or metastatic disease?"
3. "Have I progressed to castration-resistant disease?"
4. "What prior treatments have I received, and how does that affect trial eligibility?"

About specific trials: 5. "Is there a PARP inhibitor trial I could enter given my HRR mutations?" 6. "Am I a candidate for Lutetium-177 PSMA therapy? Do I need PSMA PET imaging first?" 7. "Are there trials testing new combinations of existing drugs?" 8. "How long would trial participation last, and what does it involve?"

About logistics: 9. "Are these trials available at our cancer center, or would I need to travel?" 10. "Does the trial cover treatment costs? What about travel or other expenses?" 11. "Can I stop the trial if I experience serious side effects?" 12. "How will we know if the trial treatment is working?"

---

Regarding Your Specific Questions

"What are the potential side effects of null treatments?"

I want to clarify: Did you mean "null" treatments or were you asking about a specific treatment? If you're asking about PARP inhibitors or Lutetium-177 PSMA, I can provide detailed side effect information. Please clarify, and I'll give you specific guidance.

"Should I get an Oncotype DX test to determine if I need chemotherapy?"

Oncotype DX is primarily used for early-stage prostate cancer to predict recurrence risk and help decide between active surveillance and treatment. If you already have recurrent disease, your situation is different. According to NCCN Guidelines, the decision about chemotherapy in recurrent/